Endometrial Cancers in <i>BRCA1</i> or <i>BRCA2</i> Germline Mutation Carriers: Assessment of Homologous Recombination DNA Repair Defects

Abstract

A subset of g<i>BRCA1/2</i>-associated ECs harbor biallelic <i>BRCA1/2</i> alterations and genomic features of HRD, which may benefit from homologous recombination-directed treatment regimens. ECs in <i>BRCA2</i> mutation carriers might be sporadic and even MSI high, and may potentially benefit from immune-checkpoint inhibition.